ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BDTX / financials
ENGN (34) VYGR (15) LENZ (25) AVXL (32) ⌘ Pro Terminal →

Black Diamond Therapeutics Inc. (BDTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.75 -1.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.74

Black Diamond Therapeutics Inc. (BDTX) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $102.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BDTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BDTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Black Diamond Therapeutics Inc. (NASDAQ: BDTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.75 (-1.68% 1D, market cap $102.3M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, BDTX ranks #398 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BDTX compare to ENGN and VYGR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BDTX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 10.8%. By comparison, ENGN (enGene Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $102.5M) and VYGR (Voyager Therapeutics Inc.) posts a E grade (15/100 RQD, P/E N/A, ROIC -35.0%, cap $106.0M). Among the 5-stock peer group, BDTX leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BDTX?
▼

Per BDTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701541), Black Diamond Therapeutics Inc. generated $35.1M in revenue (-84.1% YoY), $22.37B in net income, and $29.6M in free cash flow against $143.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.74 (-0.49%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 84.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (10)Whales (5)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
$5 Bull$2 Base$1 Bear
📬 FREE BDTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BDTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY BDTX SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 84.5% FCF Margin ($29.6M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
52
Grade C-$1.77+2.3% Next Q
Q2 (-2Q)
49
Grade D$1.81-6.6% Next Q
Q3 (-1Q)
47
Grade D$1.69+3.6% Next Q
Current
44
Grade D$1.75-6.5% Hist 90D α
Trajectory: C- (52) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BDTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BDTX currently carries a cautious 44/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.94) and Max Pain ($1.84) forces dealer call-delta covering toward $5.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BDTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BDTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How BDTX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$29.6M (84.5% FCF Margin)
Revenue$35.1MGross Profit $18.2M (52%)Cost of Sales $16.8MOp Profit $12.5M (35.7%)OpEx (R&D/SG&A) $5.7MNet Profit$22.37B (63793.4%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $242.1M
FY24
Rev $220.6M
FY25
Rev $35.1M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$35.1M52%35.7%$22.37B$29.6M10.8%
FY 2024$220.6M52%-35.7%-$69.68B-$62.3M-45%
FY 2023$242.1M52%-35.7%-$82.4M-$66.7M10.8%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BDTX)

  • ✓Walkthrough of BDTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BDTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.19%▼ DESCENDING CHANNEL
2026-11-03O $1.86H $1.86L $1.75C $1.75VOL 520.2K
RES: $2.10SUP: $1.40SMA50: $1.94SMA200: $2.19
$4.14$3.45$2.76$2.07$1.39RES $2.10SUP $1.40$1.752026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BDTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BDTX Butterfly Map → + Track BDTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-4.0%/yr Implied 5Y Growth

vs. -84.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BDTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BDTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BDTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BDTX)

Health Care Rank #398 of 1015 ⚔️ ENGN vs BDTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BDTX vs. ENGN, VYGR, LENZ, AVXL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Black Diamond Therapeutics Inc. (BDTX) ranks #398 by composite RQD confidence (44/100, grade D) and #649 by equity capitalization ($102.3M). Within this direct 5-issuer industry benchmark cohort, BDTX leads on earnings valuation at N/A trailing P/E, while BDTX leads on capital efficiency and profitability with 10.8% ROIC and — gross margin. BDTX currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BDTX ACTIVE
Black Diamond Therapeutics Inc.
D 44/100 — — 10.8% -1.68% $102.3M Benchmark Subject
ENGN
enGene Therapeutics Inc.
E 34/100 — — -35.0% -5.23% $102.5M /engn-vs-bdtx →
VYGR
Voyager Therapeutics Inc.
E 15/100 — — -35.0% +3.49% $106.0M /vygr-vs-bdtx →
LENZ
LENZ Therapeutics Inc.
E 25/100 — 96.0% -27.8% 0.00% $95.8M /lenz-vs-bdtx →
AVXL
Anavex Life Sciences Corp.
E 32/100 — — -35.0% -4.20% $110.3M /avxl-vs-bdtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001701541 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Black Diamond Therapeutics Inc. (BDTX) reported GAAP revenue of $35.1M (-84.1% vs. FY2024 revenue of $220.6M , and -85.5% cumulative change since FY2023) , GAAP net income of $22.37B, operating cash flow of $29.6M, and free cash flow of $29.6M (+147.5% YoY). On the balance sheet, BDTX closed FY2025 with $143.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $35.1M $22.37B $29.6M $29.6M $143.0M —
FY2024 (FY) 2024-12-31 $220.6M -$69.68B -$62.3M -$62.3M $122.6M —
FY2023 (FY) 2023-12-31 $242.1M -$82.4M -$66.7M -$66.7M — —

3. BDTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BDTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Black Diamond Therapeutics Inc. (NASDAQ: BDTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.75 (-1.68% 1D, market cap $102.3M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, BDTX ranks #398 in composite RQD confidence.

How does BDTX compare to ENGN and VYGR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BDTX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 10.8%. By comparison, ENGN (enGene Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $102.5M) and VYGR (Voyager Therapeutics Inc.) posts a E grade (15/100 RQD, P/E N/A, ROIC -35.0%, cap $106.0M). Among the 5-stock peer group, BDTX leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BDTX?

Per BDTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701541), Black Diamond Therapeutics Inc. generated $35.1M in revenue (-84.1% YoY), $22.37B in net income, and $29.6M in free cash flow against $143.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BDTX trading relative to its 50-day, 200-day, and 52-week technical levels?

BDTX last traded at $1.75 (-1.68% on volume of 494,385 shares), positioning the stock -9.79% below its 50-day simple moving average ($1.94) and -20.09% below its 200-day simple moving average ($2.19). Across its 52-week range of $1.60 to $4.94, BDTX sits at the 4.5% percentile with a 14-day RSI of 45.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.53 to $1.97).

Direct Sub-Reports: BDTX RQD Cockpit BDTX 12M Forecast BDTX Earnings & Move BDTX Dividends & DRIP BDTX Insiders & 13F BDTX Whale Options BDTX Profit Sankey BDTX News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

BDTX — Black Diamond Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Black Diamond Therapeutics Inc. (BDTX) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.75 (-1.68% 1D, market capitalization $102.3M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of 10.8%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Black Diamond Therapeutics Inc. (BDTX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Black Diamond Therapeutics Inc. (BDTX) reported $35.1M in annual revenue (up from $220.6M in FY2024, -84.1% YoY) and $22.37B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($242.1M revenue, -$82.4M net income) through FY2025, BDTX scaled operating cash flow to $29.6M and free cash flow to $29.6M, backed by $143.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $1.60 – $4.94 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation and 6.9x EV/EBITDA against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlation partners are therefore — The only sector context available is the classification as Health Care / Biotechnology: Biological Products. An investor should watch for second-order effects from the company's pipeline and partnering arrangements, but none are documented in the source data.

  • Key Question #1: Can BDTX sustain or expand its — operating margin and 10.8% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $35.1M and free cash flow of $29.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BDTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BDTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Black Diamond Therapeutics Inc. (BDTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BDTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BDTX Bull vs. Bear Conversation Board — What's Your Call at $1.75?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BDTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BDTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $2.28 (+28.1%)
📌 Pinned Debate

FY 2025 operating income turned positive at $12.5M and free cash flow reached $29.6M, a sharp reversal from prior-year losses.

Picked up a starter position in BDTX in my $100K Virtual Cash book at $1.78. FY 2025 operating income turned positive at $12.5M and free cash flow reached $29.6M, a sharp reversal from prior-year losses.. Trading inside a $1.60–$4.94 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

RetailWhale_TX 🐂 BULL

@RiskArb_Desk Shorting a 5/20 institutional whale-flow stock at $1.78 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $1.48 (-16.9%)
Spot @ $1.78

The company reports zero revenue in every period while carrying a $106.9M market cap and an FCF yield of 0%.

Careful chasing BDTX at $1.78. The company reports zero revenue in every period while carrying a $106.9M market cap and an FCF yield of 0%.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.48 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%